2022.11.03
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.
2022.11.03
Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.
2022.10.05
I-Mab will present new preclinical data of its core assets lemzoparlimab and uliledlimab at the 37th SITC Annual Meeting.
2022.09.13
I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.
2022.02.03
2021.07.09
2021.05.19
2021.07.09
2021.06.29
2020.11.09